Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Obstructive Lung Diseases

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 37 articles:
HTML format
Text format



Single Articles


    February 2018
  1. THE LANCET
    Asthma in US children.
    Lancet. 2018;391:632.
    PubMed     Text format    


    January 2018
  2. MOSLER G, Euba T
    Taking control through drama.
    Lancet. 2018;391:303-304.
    PubMed     Text format    


  3. WATTS G
    Ian Pavord: engaging with the eosinophil.
    Lancet. 2018;391:301.
    PubMed     Text format    


  4. CROOKS MG, Faruqi S, Morice AH
    How does azithromycin improve asthma exacerbations?
    Lancet. 2018;391:28.
    PubMed     Text format    


  5. GIBSON PG
    How does azithromycin improve asthma exacerbations? - Author's reply.
    Lancet. 2018;391:28-29.
    PubMed     Text format    


    December 2017
  6. PAPI A, Brightling C, Pedersen SE, Reddel HK, et al
    Asthma.
    Lancet. 2017 Dec 19. pii: S0140-6736(17)33311.
    PubMed     Text format     Abstract available


  7. SINHARAY R, Gong J, Barratt B, Ohman-Strickland P, et al
    Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants aged 60 years and older with chronic lung or heart disease and age-matched healthy controls: a randomised, cr
    Lancet. 2017 Dec 5. pii: S0140-6736(17)32643.
    PubMed     Text format     Abstract available


    September 2017
  8. DAVIES P, Bradley C
    Vanishing lung syndrome: giant bullous emphysema.
    Lancet. 2017 Sep 28. pii: S0140-6736(17)32246.
    PubMed     Text format    


  9. PAVORD ID, Beasley R, Agusti A, Anderson GP, et al
    After asthma: redefining airways diseases.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)30879.
    PubMed     Text format    


  10. KLEINERT S, Horton R
    After asthma: airways diseases need a new name and a revolution.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32205.
    PubMed     Text format    


  11. CAMARGO CA JR
    Transformational thinking about asthma.
    Lancet. 2017 Sep 11. pii: S0140-6736(17)32126.
    PubMed     Text format    


  12. WOODCOCK A, Vestbo J, Bakerly ND, New J, et al
    Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: an open-label, parallel group, randomised controlled trial.
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32397.
    PubMed     Text format     Abstract available


  13. GIBSON P
    Effectiveness trials in asthma: time to SaLSA?
    Lancet. 2017 Sep 8. pii: S0140-6736(17)32398.
    PubMed     Text format    


    August 2017
  14. JENKINS C
    Eliminating asthma deaths: have we stalled?
    Lancet. 2017 Aug 7. pii: S0140-6736(17)31587.
    PubMed     Text format    


  15. EBMEIER S, Thayabaran D, Braithwaite I, Benamara C, et al
    Trends in international asthma mortality: analysis of data from the WHO Mortality Database from 46 countries (1993-2012).
    Lancet. 2017 Aug 7. pii: S0140-6736(17)31448.
    PubMed     Text format     Abstract available


    July 2017
  16. GIBSON PG, Yang IA, Upham JW, Reynolds PN, et al
    Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial.
    Lancet. 2017 Jul 4. pii: S0140-6736(17)31281.
    PubMed     Text format     Abstract available


  17. BRUSSELLE G, Pavord I
    Azithromycin in uncontrolled asthma.
    Lancet. 2017 Jul 4. pii: S0140-6736(17)31547.
    PubMed     Text format    


    March 2017
  18. FITZGERALD JM, Emery P
    Modifying the trajectory of asthma-are there lessons from the use of biologics in rheumatology?
    Lancet. 2017;389:1082-1084.
    PubMed     Text format    


    February 2017
  19. THE LANCET
    Complexities of care in COPD.
    Lancet. 2017;389:574.
    PubMed     Text format    


    January 2017
  20. THE LANCET
    Clinical guidance for bronchiolitis.
    Lancet. 2017;389:128.
    PubMed     Text format    


  21. FLORIN TA, Plint AC, Zorc JJ
    Viral bronchiolitis.
    Lancet. 2017;389:211-224.
    PubMed     Text format     Abstract available


    December 2016
  22. WENZEL SE, Jayawardena S, Graham NM, Pirozzi G, et al
    Severe asthma and asthma-chronic obstructive pulmonary disease syndrome - Authors' reply.
    Lancet. 2016;388:2742.
    PubMed     Text format    


  23. XIA Y, Cao C, Li W, Shen H, et al
    Severe asthma and asthma-chronic obstructive pulmonary disease syndrome.
    Lancet. 2016;388:2741-2742.
    PubMed     Text format    


    November 2016
  24. PAPI A, Fabbri LM
    Management of patients with early mild asthma and infrequent symptoms.
    Lancet. 2016 Nov 29. pii: S0140-6736(16)32111.
    PubMed     Text format    


  25. REDDEL HK, Busse WW, Pedersen S, Tan WC, et al
    Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.
    Lancet. 2016 Nov 29. pii: S0140-6736(16)31399.
    PubMed     Text format     Abstract available


    October 2016
  26. GUAN WJ, Zheng XY, Chung KF, Zhong NS, et al
    Impact of air pollution on the burden of chronic respiratory diseases in China: time for urgent action.
    Lancet. 2016;388:1939-1951.
    PubMed     Text format     Abstract available


    September 2016
  27. FITZGERALD JM, Bleecker ER, Nair P, Korn S, et al
    Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    Lancet. 2016 Sep 5. pii: S0140-6736(16)31322.
    PubMed     Text format     Abstract available


  28. CALVERLEY PM
    COPD therapy: if two is good, is three better?
    Lancet. 2016;388:937-8.
    PubMed     Text format    


  29. THE LANCET
    Simplifying therapy for COPD.
    Lancet. 2016;388:936.
    PubMed     Text format    


  30. SINGH D, Papi A, Corradi M, Pavlisova I, et al
    Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial.
    Lancet. 2016;388:963-73.
    PubMed     Text format     Abstract available


  31. CASTRO M, Bacharier LB
    Treatment for severe eosinophilic asthma-consistent effect of anti-interleukin-5 antibodies?
    Lancet. 2016 Sep 2. pii: S0140-6736(16)31537.
    PubMed     Text format    


  32. BLEECKER ER, FitzGerald JM, Chanez P, Papi A, et al
    Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
    Lancet. 2016 Sep 2. pii: S0140-6736(16)31324.
    PubMed     Text format     Abstract available


    June 2016
  33. DEBAUN MR, Strunk RC
    The intersection between asthma and acute chest syndrome in children with sickle-cell anaemia.
    Lancet. 2016;387:2545-53.
    PubMed     Text format     Abstract available


  34. WATTS G
    Robert Charles Strunk.
    Lancet. 2016;387:2500.
    PubMed     Text format    


    April 2016
  35. LEVY SD, Alladina JW, Hibbert KA, Harris RS, et al
    High-flow oxygen therapy and other inhaled therapies in intensive care units.
    Lancet. 2016;387:1867-78.
    PubMed     Text format     Abstract available


  36. VESTBO J, Anderson JA, Brook RD, Calverley PM, et al
    Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial.
    Lancet. 2016;387:1817-1826.
    PubMed     Text format     Abstract available


  37. BRUSSELLE G
    Vilanterol fluticasone and mortality in comorbid COPD GOLD B.
    Lancet. 2016;387:1791-2.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Obstructive Lung Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: